Skip to main content
    D

    Dyne Therapeutics Inc (DYN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $16.02
    -0.68 (-4.07%)

    Market Cap: $3.13B

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Dyne Therapeutics Inc (DYN) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Dyne Therapeutics (DYN) has a market cap of $3.13B and an enterprise value of $2.43B. Its share count is up 28.17% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 22.36% below the market cap, as cash exceeds debt.

    Market Cap$3.13B
    Enterprise Value$2.43B
    Latest price (Nov 17, 2026)$16.02

    Key Dates

    The next earnings report is expected on Mar 1, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 1, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 9.86% in the quarter ended Sep 30, 2026 and grew 34.23% a year over 2 years.

    Shares Outstanding181.77M
    Shares Change (YoY)+28.17%
    Shares Change (QoQ)+9.86%
    Share Count Growth (2Y CAGR)+34.23%

    Price Statistics

    The stock is down 14.74% over 52 weeks and trades 4.19% below its 50-day average.

    Beta (1Y)1.80
    52-Week Change-14.74%
    1-Month Change+5.19%
    3-Month Change-40.18%
    6-Month Change+0.63%
    5-Year Change+15.02%
    Total Return (1Y)-14.74%
    Total Return (3Y CAGR)+13.28%
    Total Return (5Y CAGR)+0.08%
    Return vs SPY (1Y)-35.13%
    Max Drawdown (1Y)-46.79%
    Max Drawdown (3Y)-85.52%
    Sharpe Ratio (1Y)-0.42
    Correlation with SPY (1Y)0.39
    50-Day Average$16.72
    200-Day Average$19.30
    52-Week Range$14.00 to $27.30
    RSI (14 Days)41.9
    Average Volume (20 Days)2.34M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 12.99x current liabilities, and total debt is 0.23x shareholder equity.

    Current Ratio12.99x
    Quick Ratio12.99x
    Debt / Equity0.23x
    Interest Coverage-34.61x

    Returns and Efficiency

    Return on invested capital is -42.87% over the last 12 months, against a 5-year average of -32.67%.

    Return on Equity (ROE)-64.98%
    Return on Assets (ROA)-48.99%
    Return on Invested Capital (ROIC)-42.87%
    ROE (5Y Average)-92.38%
    ROA (5Y Average)-63.28%
    ROIC (5Y Average)-32.67%

    Scores

    DYN has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit-$521.00K
    Operating Income-$620.14M
    Pretax Income-$604.92M
    Net Income-$604.92M
    Reported EPS (TTM)-$3.60

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 75.69% of the $1.23B in total assets.

    Cash and Equivalents$913.20M
    Total Debt$213.32M
    Net Cash$699.88M
    Net Cash Per Share$3.85
    Working Capital$1.09B
    Shareholder Equity$930.93M
    Book Value Per Share$5.12
    Total Assets$1.23B
    Total Liabilities$303.87M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $4.23M of capital spending, operating cash flow left -$568.76M of free cash flow.

    Operating Cash Flow-$564.53M
    Capital Expenditures$4.23M
    Free Cash Flow-$568.76M
    FCF Per Share-$3.05
    Depreciation and Amortization$2.89M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)+125.61%
    Tangible Book Per Share Growth (2Y CAGR)+125.61%

    Revenue and profit by year

    Dividends and Yields

    DYN does not pay a dividend. Its free cash flow yield is -19.53%.

    FCF Yield-19.53%
    Buyback Yield-26.88%
    Shareholder Yield-26.88%

    Peer Position

    Against 4 similar companies, DYN has the 4th highest ROIC.

    ROIC-42.87% vs -34.87% median
    Revenue Growth (Trailing 4 Quarters, YoY)-100.00% vs -82.99% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About DYN

    What is DYN's market cap?

    Dyne Therapeutics has a market cap of $3.13B. Its enterprise value, which adds debt and subtracts cash, is $2.43B.

    How many shares of DYN are outstanding?

    Dyne Therapeutics has 181.77M shares outstanding. The count is up 28.17% from a year earlier.

    Does DYN pay a dividend?

    No. Dyne Therapeutics does not pay a dividend.

    How much debt does DYN have?

    Dyne Therapeutics has $213.32M of total debt and $913.20M of cash and equivalents, a net cash position of $699.88M.